(Q35018460)

5 August 2017

1 reference

title

Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents (English)

1 reference

5 August 2017

main subject

irritable bowel syndrome

1 reference

2

Alexander C Ford

0 references

author name string

Anita Sainsbury

series ordinal

1

1 reference

5 August 2017

language of work or name

1 reference

1 March 2011

1 reference

Therapeutic Advances in Gastroenterology

5 August 2017

published in

1 reference

5 August 2017

volume

4

1 reference

5 August 2017

issue

2

1 reference

5 August 2017

page(s)

115-127

1 reference

Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Evidence for intestinal chloride secretion

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

A randomized controlled trial of imipramine in patients with irritable bowel syndrome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

A synthetic prostone activates apical chloride channels in A6 epithelial cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

A placebo-controlled trial of prucalopride for severe chronic constipation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Somatic comorbidities of irritable bowel syndrome: a systematic analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Antidepressants for neuropathic pain

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Guidelines on the irritable bowel syndrome: mechanisms and practical management.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Tricyclic antidepressant pharmacology and therapeutic drug interactions updated

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Irritable bowel syndrome in twins: genes and environment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Design of treatment trials for functional gastrointestinal disorders

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Functional bowel disorders

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

STa and cGMP stimulate CFTR translocation to the surface of villus enterocytes in rat jejunum and is regulated by protein kinase G

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Spectrum of use and tolerability of 5-HT3 receptor antagonists

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Probiotics for treating infectious diarrhoea

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Familial aggregation of irritable bowel syndrome: a prospective study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

The effects of relaxation response meditation on the symptoms of irritable bowel syndrome: results of a controlled treatment study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

The inhibition of cholera toxin-induced 5-HT release by the 5-HT(3) receptor antagonist, granisetron, in the rat.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

The treatment of irritable bowel syndrome with hypnotherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Functional bowel disorders and functional abdominal pain

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Symptoms of irritable bowel syndrome in ulcerative colitis in remission

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Rectosigmoid motility in patients with quiescent and active ulcerative colitis.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Towards positive diagnosis of the irritable bowel

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome

8 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Roles of calcitonin gene-related peptide in maintenance of gastric mucosal integrity and in enhancement of ulcer healing and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

"Power" of selective serotonin reuptake inhibitors in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

An exploratory study of the association of adrenergic and serotonergic genotype and gastrointestinal motor functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Small intestinal bacterial overgrowth recurrence after antibiotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Use of serum biomarkers in a diagnostic test for irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Association of the -1438 G/A and 102 T/C polymorphism of the 5-Ht2A receptor gene with irritable bowel syndrome 5-Ht2A gene polymorphism in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Preliminary study of a self-administered treatment for irritable bowel syndrome: comparison to a wait list control group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

Postinfective diarrhoea and bile acid malabsorption.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms

25 October 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10387203

GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105621

Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles

9 December 2018

1 reference

12 December 2020

Development of probiotics as biologic drugs

1 reference

12 December 2020

Relaxation training as a treatment for irritable bowel syndrome

1 reference

12 December 2020

Involvement of serotonergic mechanisms in initiation of small intestine cyclic motor events

1 reference

12 December 2020

Activation of the mucosal immune system in irritable bowel syndrome

1 reference

12 December 2020

Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome

1 reference

12 December 2020

Yoghurt with Bifidobacterium longum reduces erythromycin-induced gastrointestinal effects

1 reference

12 December 2020

Psychological factors in the irritable bowel syndrome

1 reference

12 December 2020

Bran and irritable bowel syndrome: The primary-care perspective

1 reference

12 December 2020

Glaxo Wellcome withdraws irritable bowel syndrome medication

1 reference

12 December 2020

Cognitive therapy for irritable bowel syndrome

1 reference

12 December 2020

Identifying dyspepsia and irritable bowel syndrome: the value of pain or discomfort, and bowel habit descriptors

1 reference

12 December 2020

Lactobacilli to prevent traveler's diarrhea?

1 reference

12 December 2020

Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety

1 reference

12 December 2020

A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome

1 reference

12 December 2020

Two controlled evaluations of multicomponent psychological treatment of irritable bowel syndrome

1 reference

12 December 2020

Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR

1 reference

12 December 2020

Small intestinal bacterial overgrowth and the irritable bowel syndrome

1 reference

12 December 2020

Irritable Bowel Syndrome–Type Symptoms in Patients With Inflammatory Bowel Disease: A Real Association or Reflection of Occult Inflammation?

1 reference

12 December 2020

The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756283X10387203

1 reference

5 August 2017

1 reference

5 August 2017

1 reference